Literature DB >> 24964695

Measurement of costs for health economic evaluation.

Arthorn Riewpaiboon.   

Abstract

The provision of guidelines on cost measurement for health economic evaluations enable research to be more standardized and hence more comparable, which offers clear benefits for policy formulation and health management. The guidelines herein focus on three aspects-the cost of health intervention/health care programs, the cost of illness/health risks, and use of costs in health economic evaluation. For each aspect, the main concepts and methods are outlined, and recommendations for the Thai context are presented. There is particular focus on how to calculate various costs according to different evaluation methods and perspectives, how to evaluate source of cost data, how to make value adjustments and how to present cost measurement findings.

Mesh:

Year:  2014        PMID: 24964695

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  14 in total

1.  Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.

Authors:  Rungroj Krittayaphong; Unchalee Permsuwan
Journal:  Am J Cardiovasc Drugs       Date:  2022-07-07       Impact factor: 3.283

2.  Cost-Utility Analysis Compared Between Radiotherapy Alone and Combined Surgery and Radiotherapy for Symptomatic Spinal Metastases in Thailand.

Authors:  Pasawat Taechalertpaisarn; Sirichai Wilartratsami; Pochamana Phisalprapa; Chayanis Kositamongkol; Achiraya Teyateeti; Panya Luksanapruksa
Journal:  Neurospine       Date:  2022-05-12

3.  Economic Evaluation of Human Rotavirus Vaccine in Thailand.

Authors:  Surasak Saokaew; Wasana Prasitsuebsai; Gyneth Lourdes Bibera; Kirati Kengkla; Xu-Hao Zhang; Kyu-Bin Oh; Christa Lee
Journal:  Infect Dis Ther       Date:  2019-06-13

4.  Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand.

Authors:  Unchalee Permsuwan; Piyameth Dilokthornsakul; Surasak Saokaew; Kednapa Thavorn; Nathorn Chaiyakunapruk
Journal:  Clinicoecon Outcomes Res       Date:  2016-09-21

5.  Treatment cost and costing model of obstetric complications at a hospital in Myanmar.

Authors:  A Thi Win Shwe; Arthorn Riewpaiboon; Usa Chaikledkaew; Sitaporn Youngkong
Journal:  PLoS One       Date:  2019-03-20       Impact factor: 3.240

6.  Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions.

Authors:  Stavros Simeonidis; Stefania Koutsilieri; Athanassios Vozikis; David N Cooper; Christina Mitropoulou; George P Patrinos
Journal:  Front Pharmacol       Date:  2019-08-02       Impact factor: 5.810

7.  Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review.

Authors:  Akira Yuasa; Naohiro Yonemoto; Michael LoPresti; Shunya Ikeda
Journal:  Pharmacoeconomics       Date:  2020-11-24       Impact factor: 4.981

Review 8.  Cost transferability problems in economic evaluation as a framework for an European health care and social costs database.

Authors:  Leticia García-Mochón; Joan Rovira Forns; Jaime Espin
Journal:  Cost Eff Resour Alloc       Date:  2021-07-18

9.  The cost utility and budget impact of adjuvant racecadotril for acute diarrhea in children in Thailand.

Authors:  Tamlyn Anne Rautenberg; Ute Zerwes
Journal:  Clinicoecon Outcomes Res       Date:  2017-07-17

10.  Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction.

Authors:  Rungroj Krittayaphong; Jirawit Yadee; Unchalee Permsuwan
Journal:  Clinicoecon Outcomes Res       Date:  2019-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.